Equities

Summit Therapeutics Inc

SMMT:NMQ

Summit Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)18.84
  • Today's Change0.42 / 2.28%
  • Shares traded82.55k
  • 1 Year change+866.15%
  • Beta-0.9162
Data delayed at least 15 minutes, as of Nov 22 2024 14:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments18634972
Total Receivables, Net0.856.1217
Total Inventory------
Prepaid expenses2.441.507.16
Other current assets, total0.183001.20
Total current assets19065797
Property, plant & equipment, net6.065.083.48
Goodwill, net1.891.802.01
Intangibles, net--010
Long term investments------
Note receivable - long term0.96----
Other long term assets4.320.580.17
Total assets203664113
LIABILITIES
Accounts payable2.670.364.37
Accrued expenses171812
Notes payable/short-term debt0200
Current portion long-term debt/capital leases------
Other current liabilities, total0.720.668.84
Total current liabilities203926
Total long term debt1004950
Total debt1005140
Deferred income tax------
Minority interest------
Other liabilities, total4.854.194.47
Total liabilities12553830
SHAREHOLDERS EQUITY
Common stock7.022.110.98
Additional paid-in capital1,066505384
Retained earnings (accumulated deficit)(993)(378)(300)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(2.45)(1.89)(2.2)
Total equity7812783
Total liabilities & shareholders' equity203664113
Total common shares outstanding70221198
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.